The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate […]
Silicone patch for laser-assisted tattoo removal wins new FDA clearance
Merz North America said today that its Describe PFD patch was cleared by the FDA for all commonly-used lasers. The single-use, perfluorodecalin-infused patch is used during laser-assisted tattoo removal to allow for multiple passes in a single treatment session. Get the full story at our sister site, Drug Delivery Business News.
Acelity taps Eckert to succeed Woody as CEO| Personnel Moves | April 5, 2017
Acelity said today it tapped R. Eckert as its new prez & CEO, succeeding Joseph Woody who is stepping away from Acelity following the company’s divestiture of its LifeCell division earlier this year. Eckert previously served as CEO of health information tech company TriZetto Corp, and has led 5 other companies including CRC Health Group, Eclipsys […]
Merz buys tattoo-removal company ON Light Sciences
Healthcare company Merz said today it picked up On Light Sciences, makers of the DeScribe Transparent perfluorodecalin patch designed for laser tattoo removal, for an undisclosed amount. Raleigh, N.C.-based Merz said the DeScribe device has FDA 510(k) clearance and CE Mark approval in the European Union for the device, and that the patch will be folded […]
Medtronic shareholder sues to block pending merger with Covidien | The week in medtech M&A
Ulthera pulls $86M IPO in favor of $600M merger
Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.
Diabetes: Medtronic wins clearance for next-gen clinical continuous glucose monitor | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.
